Focused On-demand Library for Solute carrier family 2, facilitated glucose transporter member 1

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

P11166

UPID:

GTR1_HUMAN

Alternative names:

Glucose transporter type 1, erythrocyte/brain; HepG2 glucose transporter

Alternative UPACC:

P11166; A8K9S6; B2R620; D3DPX0; O75535; Q0P512; Q147X2

Background:

Solute carrier family 2, facilitated glucose transporter member 1 (SLC2A1), also known as Glucose transporter type 1, plays a pivotal role in glucose uptake. It is essential for basal glucose transport across the blood-brain barrier, ensuring the brain's energy supply. SLC2A1's broad substrate specificity allows it to transport various aldoses, highlighting its critical function in energy metabolism.

Therapeutic significance:

SLC2A1's dysfunction is linked to several neurological disorders, including GLUT1 deficiency syndrome 1 and 2, Epilepsy, idiopathic generalized 12, Dystonia 9, and Stomatin-deficient cryohydrocytosis with neurologic defects. These associations underscore the protein's potential as a target for therapeutic intervention in a range of neurologic conditions.